Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 6;10(8):e0134904.
doi: 10.1371/journal.pone.0134904. eCollection 2015.

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates

Benoit Visseaux  1 , Charlotte Charpentier  1 , Gilles Collin  1 , Mélanie Bertine  1 , Gilles Peytavin  2 , Florence Damond  1 , Sophie Matheron  3 , Eric Lefebvre  4 , Françoise Brun-Vézinet  1 , Diane Descamps  1 ; ANRS CO5 HIV-2 Cohort
Collaborators, Affiliations

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates

Benoit Visseaux et al. PLoS One. .

Abstract

Background: Maraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of this study was to assess HIV-2 susceptibility to cenicriviroc, a novel, once-daily, dual CCR5 and CCR2 antagonist that has completed Phase 2b development in HIV-1 infection.

Methods: Cenicriviroc phenotypic activity has been tested using a PBMC phenotypic susceptibility assay against four R5-, one X4- and one dual-tropic HIV-2 clinical primary isolates. All isolates were obtained by co-cultivation of PHA-activated PBMC from distinct HIV-2-infected CCR5-antagonist-naïve patients included in the French HIV-2 cohort and were previously tested for maraviroc susceptibility using the same protocol. HIV-2 tropism was determined by phenotypic assay using Ghost(3) cell lines.

Results: Regarding the 4 R5 HIV-2 clinical isolates tested, effective concentration 50% EC50 for cenicriviroc were 0.03, 0.33, 0.45 and 0.98 nM, similar to those observed with maraviroc: 1.13, 0.58, 0.48 and 0.68 nM, respectively. Maximum percentages of inhibition (MPI) of cenicriviroc were 94, 94, 93 and 98%, similar to those observed with maraviroc (93, 90, 82, 100%, respectively). The dual- and X4-tropic HIV-2 strains were resistant to cenicriviroc with EC50 >1000 nM and MPI at 33% and 4%, respectively.

Conclusions: In this first study assessing HIV-2 susceptibility to cenicriviroc, we observed an in vitro activity against HIV-2 R5-tropic strains similar to that observed with maraviroc. Thus, cenicriviroc may offer a once-daily treatment opportunity in the limited therapeutic arsenal for HIV-2. Clinical studies are warranted.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Eric Lefebvre is Chief Medical Officer for Tobira Pharmaceutics. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Dose response curves for cenicriviroc-dependent inhibition (A) and maraviroc-dependent inhibition (B).
R5, dual and X4-tropic HIV-2 strains are depicted in continuous, dashed and dotted black lines, respectively. HIV-1 R5-tropic strain is depicted using the continuous gray line.
See this image and copyright information in PMC

References

    1. Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev. 2005;7: 139–147. - PubMed
    1. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA. 2002;99: 14410–14415. 10.1073/pnas.222366699 - DOI - PMC - PubMed
    1. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother. 2008;52: 1545–1548. 10.1128/AAC.01284-07 - DOI - PMC - PubMed
    1. Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, et al. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors. Antimicrob Agents Chemother. 2012;56: 137–139. 10.1128/AAC.05313-11 - DOI - PMC - PubMed
    1. Espírito-Santo M, Santos-Costa Q, Calado M, Dorr P, Azevedo Pereira JM. Susceptibility of HIV-2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands and small molecule inhibitors. AIDS Research and Human Retroviruses. 2011; 10.1089/AID.2011.0124 - DOI - PMC - PubMed

Publication types

MeSH terms